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Abstract
Background—Norovirus and rotavirus are prominent enteric viruses responsible for severe 
acute gastroenteritis disease burden around the world. Both viruses recognize and bind to histo-
blood group antigens, which are expressed by the fucosyltransferase 2 (FUT2) gene. Individuals 
with a functional FUT2 gene are termed “secretors.” FUT2 polymorphisms may influence viral 
binding patterns and, therefore, may influence host susceptibility to infection by these viruses.
Methods—We performed a systematic review of the published literature on this topic. Data were 
abstracted and compiled for descriptive analyses and metaanalyses. We estimated pooled odds 
ratios (ORs) for infection using random-effects models.
Results—We found that secretors were 9.9 times (95% confidence interval [CI], 3.9–24.8) as 
likely to be infected with genogroup II.4 noroviruses and 2.2 times as likely to be infected with 
genogroup II non-4 noroviruses (95% CI, 1.2–4.2) compared with nonsecretors. Secretors were 
also 26.6 times more susceptible to infections from P[8]-type rotaviruses compared with 
nonsecretors (95% CI, 8.3–85.0).
Conclusions—Our analyses indicate that host genetic susceptibility to norovirus and rotavirus 
infection may be strain specific. As strain distribution and the proportion of genetic phenotypes 
vary in different countries, future studies should focus on differences in susceptibility among 
various ethnicities. Knowledge of innate susceptibility to rotavirus and norovirus can lead to 
improved understanding of both vaccine performance and individual risk of disease.
Correspondence: A. Kambhampati, Centers for Disease Control and Prevention, 1600 Clifton Rd, NE, MS–A34, Atlanta, Georgia 
30333 (wyc4@cdc.gov). 
Clinical Infectious Diseases®
Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a)US 
Government employee(s) and is in the public domain in the US.
Supplementary Data
Supplementary materials are available at http://cid.oxfordjournals.org. Consisting of data provided by the author to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of the author, so questions or comments should be addressed to 
the author.
Disclaimer. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of 
the Centers for Disease Control and Prevention (CDC).
Potential conflict of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of 
Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
HHS Public Access
Author manuscript
Clin Infect Dis. Author manuscript; available in PMC 2017 January 01.
Published in final edited form as:














norovirus; rotavirus; FUT2; histo-blood group antigen
Enteric viruses, specifically norovirus and rotavirus, are a leading cause of diarrheal illness 
worldwide. Rotavirus has been associated with more than 450 000 deaths per year among 
young children, with disproportionately high levels of mortality in Asia and sub-Saharan 
Africa [1]. It is estimated that norovirus is associated with approximately 18% of all cases of 
acute gastroenteritis [2]. In populations with widespread rotavirus vaccination, norovirus has 
been recognized as the predominant cause of acute gastroenteritis in children [3, 4].
Noroviruses are a genetically diverse group of RNA viruses, consisting of at least 6 
genogroups (G) [5]. Two genogroups, GI and GII, are responsible for the majority of human 
illnesses; together, these groups include more than 30 genotypes. Most outbreaks are caused 
by GII.4 noroviruses, which undergo rapid antigenic evolution, giving rise to a new 
predominant strain every 2 to 4 years [6, 7]. Novel GII.4 strains are often associated with 
increased morbidity and mortality [8, 9].There are currently no licensed vaccines available 
for protection against norovirus. However, one vaccine is entering phase III clinical trials, 
and other potential vaccines are in various stages of development [10–12].
Rotaviruses are double-stranded RNA viruses with a genome consisting of 11 segments. 
They are classified according to the genes that code for 2 surface proteins, VP7 (or G, 
glycoprotein) and VP4 (P, protease sensitive) [13]. Gene reassortment of these proteins can 
lead to several strains of rotavirus. However, 3 P-genotypes, P[8], P[6], and P[4], are 
responsible for the majority of human rotavirus infections [13]. Two rotavirus vaccines have 
been licensed and are used throughout the world; both vaccines contain a P[8] component 
[14].
Both norovirus and rotavirus recognize and bind to histo-blood group antigens (HBGA), 
which are oligosaccharides found in the epithelial cells of the gastrointestinal and respiratory 
tracts, as well in saliva and other secretions [15, 16]. The expression of HBGA on the gut 
surface epithelium is controlled by the fucosyltransferase 2 (FUT2) gene, which encodes 
alpha (1, 2) fucosyltransferase in order to generate H-antigens. In turn, H-antigens are 
catalyzed by enzymes to produce A or B blood group antigens. Numerous polymorphisms 
exist on the FUT2 gene; for example, the nucleotide 428 (G > A) nonsense mutation is most 
commonly found in European populations, while a missense mutation found at nucleotide 
385 (A > T) predominantly occurs in Asian populations [17]. Individuals with such 
polymorphisms are known as “nonsecretors” and make up about 20% of the European 
population; the remaining 80% have the functional FUT2 gene and are known as 
“secretors.” Similarly, the FUT3 gene encodes alpha (1, 3) or (1, 4) fucosyltransferase in 
order to generate Lewis antigens [18]. Approximately 6%–8% of the European population is 
Lewis negative compared with about 32% of the African population [19, 20].
Results from challenge and outbreak studies support a correlation between infection with 
norovirus or rotavirus and HBGA phenotypes. Immunity to either virus is suggested to 
occur, to a degree, in a genotype- or strain-dependent manner [21, 22]. Here, we aimed to 
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systematically describe host-genetic associations with the risk of rotavirus or norovirus by 
conducting a metaanalysis of the current literature.
METHODS
We performed a systematic review of the PubMed database to obtain peer-reviewed 
publications reporting data on norovirus or rotavirus cases and their potential association(s) 
with HBGA phenotypes [23, 24]. The full search strategy is detailed in the Supplementary 
Appendix (Supplementary Table 1). Briefly, our search included terms such as “histo blood 
group antigens,” “secretor,” “FUT2,” and other related terminology. Titles and abstracts 
were screened for relevance before assessment of full-text articles. Publications were 
included if they presented data on the number of infected or symptomatic individuals as well 
as uninfected or asymptomatic individuals among any of the following categories: secretor 
status, Lewis phenotype, and ABO blood group. We excluded publications that presented 
secondary data analysis or nonhuman data, those written in a language other than English, 
and those without a control group. We did not restrict our search strategy by study design or 
year of publication; we included all publications identified through 1 December 2014. 
Additional publications were identified through reference lists from included papers.
Data Abstraction and Variable Definition
Data on the following variables were abstracted from each publication, when available: last 
name of first author, title and year of publication, journal name, study type and setting, 
pathogen type (ie, norovirus or rotavirus), race and age of study participants, the specific 
FUT2 mutation under analysis, and the number of cases and controls. When publications 
presented multiple control groups, we compared cases with the pooled controls. Data on the 
number of infected and uninfected individuals were abstracted for the following groups: 
secretors and nonsecretors, Lewis positives and negatives (abstracted by genotype where 
presented), and blood types A, B, O, and AB. Data were stratified by pathogen genotype or 
serotype; studies that presented data on multiple genotypes were represented by multiple 
data lines.
Cases were defined as individuals with a laboratory-confirmed infection of norovirus or 
rotavirus, and controls were defined as those without a laboratory-confirmed infection. 
However, in studies in which norovirus and rotavirus cases were not laboratory tested (ie, 
outbreak summaries), symptomatic illness was considered as a proxy for infection, and 
asymptomatic or unexposed individuals were considered as controls.
Control group data were required for inclusion. However, due to the paucity of data on 
rotavirus, we included data from 1 publication on rotavirus that presented results from 2 
separate study sites, only 1 of which had control group data. For data from the study site 
without control group data, cases infected with 1 strain were compared with cases infected 
with other strains to determine odds of strain-specific infection (eg, P[4] infections were 
compared with P[6] and P[8] infections).
All individuals with FUT2 mutations were grouped as nonsecretors, regardless of the type of 
mutation. Homozygous carriers of the missense mutation found at nucleotide 385 (A > T), 
Kambhampati et al. Page 3













commonly recognized as “weak secretors,” were included in the nonsecretor category for 
analytic purposes. Additionally, since the categorization of secretor status varied among 
studies, with most studies presenting data only on secretors and nonsecretors, partial 
secretors (ie, heterozygous individuals) were classified as secretors.
Statistical Analyses
Our primary objective was to determine if the odds of norovirus or rotavirus infection were 
associated with mutations in the FUT2 gene. All publications identified through our 
systematic review were included in the metaanalysis. We estimated pooled odds ratios 
(ORs) for infection (vs no infection) between secretors and nonsecretors by using a random-
effects model stratified by genotype. When calculating ORs for study data that included zero 
individuals in any group, 0.5 was added to all groups in that study. Statistical significance 
was determined by the 95% confidence interval (CI). For analysis of norovirus infections, 
we classified genotypes into the following 3 groups: GI, GII non-4 (not including GII.4), 
and GII.4. For the rotavirus analysis, strains were separated into the following 3 groups 
based on the VP4 gene: P[4], P[6], and P[8]. We assessed the amount of residual 
heterogeneity by calculating the I2 statistic. Publication bias was assessed using Egger’s 
regression test.
We conducted 2 additional analyses to determine the odds of norovirus infection between 
Lewis-positive and Lewis-negative individuals and between individuals with O blood type 
and those with non-O blood types (A, B, and AB). Pooled ORs and 95% CIs for the 
additional analyses were generated through random-effects models.
To examine differences by study design among the norovirus studies, we conducted a meta-
regression analysis that included both genotype and study design. All analyses were 
conducted using the metafor package in R [25, 26].
RESULTS
We identified 72 publications, of which 39 full-text articles were assessed for inclusion 
(Figure 1). In total, 23 publications met our inclusion criteria; almost all were published 
between 2002 and 2014 (2 articles were pending acceptance at the time of our search and 
were subsequently accepted in early 2015) (Supplementary Tables 2 and 3). Of 23 
publications from which data were abstracted, 19 (86%) contained data only on norovirus, 
while 3 (9%) included data on rotavirus and 1 (5%) included data on both viruses. 
Publications included data on a total of 4584 individuals from 12 countries and on age 
groups ranging from children aged <5 years to the elderly. Associations between rotavirus or 
norovirus and secretor status were assessed in 22 studies (96%), with blood group in 10 
studies (46%) and with Lewis phenotype in 5 studies (23%). Of those studies that reported 
associations, 16 (72%), 4 (40%), and 2 (40%) publications reported a significant positive 
association (P < .05) between infection and secretor status, O blood type, or Lewis epitope, 
respectively.
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Overall, among 18 norovirus studies that presented data on associations with secretor status, 
secretors had 4.2 times the odds of infection when compared with nonsecretors (95% CI, 
2.3–7.9; I2 statistic, 73%; Figure 2). Secretors were 9.9 times more frequently infected with 
GII.4 noroviruses (95% CI, 3.9–24.8; I2 statistic, 38%) and 2.2 times more frequently 
infected with GII non-4 noroviruses than nonsecretors (95% CI, 1.2–4.2; I2 statistic, 34%). 
When examined overall, secretors had higher odds of infection with GI (OR, 3.4; 95% CI, .
7–16.7; I2 statistic, 87%) noroviruses, though the effect was nonsignificant. There was 
evidence of publication bias in the norovirus outcome studies taken as a whole (P < .001).
Controlling for genotype, challenge studies were significantly associated with increased 
odds of infection (P < .001). Exclusion of challenge studies from the model did not yield a 
substantial difference among the GII.4 and GII non-4 groups. When challenge studies were 
excluded from the GI group, secretors had lower odds of infection (OR, 0.8; 95% CI, .5–1.3; 
I2 statistic, 0%); this effect was nonsignificant.
Neither blood type O (compared with A, B, or AB blood type; OR, 1.5; 95% CI, .9–2.6; I2 
statistic, 64%; Figure 3) or Lewis-positive individuals (compared with Lewis negative; OR, 
1.1; 95% CI, .6–1.8; I2 statistic, 0%; Figure 4) had greater odds of norovirus infection. No 
evidence of publication bias was found for either analysis.
Rotavirus
Among 4 studies that presented data on associations between rotavirus and secretor status, 
secretors had 4.2 times the odds of infection (95% CI, 1.1–15.8; I2 statistic, 70%) with 
rotavirus overall compared with nonsecretors (Figure 5). Secretors were significantly more 
likely to have P[8] infections than nonsecretors (OR, 26.6; 95% CI, 8.3–85.0; I2 statistic, 
0%). This result was highly consistent for all studies that reported an association between 
secretor status and rotavirus. Secretor status was not significantly associated with 
susceptibility to either P[6] (OR, 0.4; 95% CI, .0–4.1; I2 statistic, 71%) or P[4] (OR, 3.6; 
95% CI, .7–19.6; I2 statistic, 0%) infections. There was no evidence of publication bias in 
the rotavirus studies.
DISCUSSION
Our analysis revealed consistent associations between secretor status and susceptibility to 
both norovirus and rotavirus infection. Secretors had increased likelihood of norovirus 
infection, and this risk was driven by susceptibility to GII norovirus infections, most 
importantly, GII.4 noroviruses. We did not find a significantly increased risk of infection 
with GI noroviruses among secretors. Interestingly, the 2 studies that reported strong 
associations with GI were both GI.1 volunteer challenge studies, supporting the notion that 
GI.1 viruses have secretor-dependent binding properties distinct from contemporary GI 
viruses. When these challenge studies were excluded from the model, the risk of GI 
infection dropped substantially, suggesting that any association between secretor status and 
susceptibility to GI infections overall may be driven by GI.1 noroviruses, which no longer 
commonly cause outbreaks [27]. While there is mechanistic evidence that Lewis phenotype 
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and ABO blood type also play a role in susceptibility to norovirus [16], we did not observe a 
clear association with infection for either. Based on the limited data on rotavirus, we found a 
similarly increased risk of infection for secretor-positive individuals, driven by a 
substantially heightened risk for P[8] rotavirus infection.
Despite the different study designs and populations, we found a good deal of consistency 
between studies. After controlling for genotype in the meta-regression model, only challenge 
studies were significantly associated with increased odds of infection; exclusion of these 
studies did not yield a considerable difference in the effect among the GII.4 and GII non-4 
groups. After accounting for different genotype profiles, most groups had little to no 
heterogeneity, as measured by the I2 statistic. The rotavirus studies had a similar pattern; 
however, studies on P[6] had a significant amount of heterogeneity. More studies on 
associations with P[6] rotavirus would help ascertain susceptibility to this type of rotavirus. 
Some of the observed heterogeneity among both the rotavirus and norovirus studies might 
be explained by variation among ethnicities and associated single nucleotide 
polymorphisms. For example, homozygous carriers of the 385 (A > T) missense mutation 
are considered “weak” secretors, as they express low levels of H-antigen, as opposed to 
“nonsecretors” with the 428 (G > A) nonsense mutation who do not secrete H-antigen. As 
the 2 mutations are different in functionality, they may also cause differences in 
susceptibility to specific strains.
Similarly, there was evidence of publication bias in the norovirus studies when examined as 
a whole. This may suggest that some negative results (ie, studies finding a lack of 
association) are not being published. This has clear implications; in order to develop a 
complete understanding of host susceptibility, data on negative associations with genetic 
predictors are as important as data on positive associations, as they may reveal variation 
among groups such as ethnicity.
Several limitations must be considered in conjunction with our findings. First, the 
publications included in our analysis represented differences in the way infected individuals 
and uninfected individuals were defined. For example, in outbreak studies, symptomatic 
individuals are considered as infected cases, even in circumstances where not all infections 
were laboratory confirmed, and therefore may have been the result of an unrelated etiology. 
Similarly for outbreak studies, the classification of controls may include some who were not 
truly exposed to the virus, as well as those who were infected but were asymptomatic. In 
contrast, challenge studies use both seroconversion as well as detection of viral RNA in 
stool samples to identify cases, resulting in a more sensitive and specific diagnosis for all 
infected individuals, including those who were asymptomatic. Another advantage of 
challenge studies compared with observational studies is that all participants are known to 
have an exposure. Because all participants in challenge studies are exposed to the virus, 
individuals defined as uninfected are truly uninfected.
Second, all of the rotavirus studies are hospital-based and, as a result, may have only 
captured severe illness. Thus, our findings may reflect susceptibility to severe illness, rather 
than susceptibility to infection. To some degree, this might have also impacted the norovirus 
results, though results from community and challenge studies appeared to be consistent.
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Another limitation was the small number of published studies that examined innate 
susceptibility to rotavirus. While we were able to assess susceptibility to norovirus based on 
secretor status, Lewis status, and blood type, we were only able to analyze the relationship 
between secretor status and rotavirus. Additional studies that focus on the association with 
rotavirus are needed to fully assess variations in susceptibility as a result of FUT2 and FUT3 
mutations.
Finally, there was incomplete geographical representation in the studies included in our 
metaanalysis. More than a quarter of the studies we included were conducted in the United 
States, and a similar number originated from European countries. Conversely, there were 
little to no data from Asian populations, specifically those of Polynesian descent, as well as 
Middle Eastern and South Asian populations. Study participants from Central and South 
American countries were also underrepresented; these countries often include large 
indigenous populations.
The lack of wide geographical representation is especially important to the topic of FUT2 
and FUT3 polymorphisms, the proportion of which varies among different ethnicities, 
potentially leading to differences in risk of infection among those populations. Some 
examples include the predominance of the missense mutation at nucleotide 385 (A > T) 
among East Asian populations and of the Lewis-negative phenotype among African 
populations [17, 28]. Notably, one study suggested that a Lewis-negative predominant 
African population in Burkina Faso was naturally protected from P[8] rotavirus infections 
[21]. Since individuals from several regions are underrepresented, we cannot extrapolate our 
results to individuals of all ethnicities, and future research should focus on these populations 
in order to determine to what extent susceptibility based on secretor status may vary among 
different ethnic groups. Research should also include consideration of the interaction 
between enteric bacteria and viruses in determining susceptibility; a recent study 
demonstrated that depletion of intestinal flora significantly reduced murine norovirus titers 
[29].
The results of our analysis suggest the potential for pharmaceutical and other therapeutic 
interventions that block the binding of norovirus and rotavirus to HBGA glycans, which 
would impede the first step of the virus infection process. Studies have shown that human 
breast milk from mothers with the secretor phenotype contains fucosylated oligosaccharides, 
which can act as such a blockade against the binding of norovirus virus–like particles [30, 
31].
These results also have implications for vaccine development and study design. As our 
analysis indicates, some individuals may be protected against infection and, further, may not 
respond to the vaccine. A recent GII.4 norovirus vaccine trial included secretor status as a 
criterion for eligibility in order to ensure susceptibility to the challenge virus [10]. Results of 
vaccine efficacy studies should be interpreted while bearing in mind the proportion of 
individuals in the study population with FUT2 or FUT3 polymorphisms. Differences in 
susceptibility to P[8] rotaviruses may also suggest that nonsecretors respond less well to 
vaccination. However, current evidence shows that both vaccines are effective against 
heterotypic and homotypic strains [32].
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In conclusion, analysis of the existing literature suggests a strong association between the 
FUT2 gene and risk of infection with GII.4 noroviruses and P[8] rotaviruses. Future 
observational studies in Asia and South and Central America and among various ethnicities 
in these regions are needed in order to understand differences in innate susceptibility to 
enteric viruses. Further, it is important to understand the potential contribution of 
commensal bacteria in order to determine susceptibility to these viruses. Understanding 
patterns of susceptibility may be useful for the development of norovirus vaccines and 
therapeutics and the application of both norovirus and rotavirus vaccines among populations 
with an increased or decreased likelihood of infection.
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Susceptibility to norovirus infection based on secretor status, by genotype. Studies that 
presented data on multiple genotypes compared with 1 control group were stratified by 
genotype and compared with the same control group. *Challenge studies are denoted with 
an asterisk. Abbreviations: CI, confidence interval; NV+, norovirus positive; NV−, 
norovirus negative; RE, random effects.
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Susceptibility to norovirus infection based on blood type. Abbreviations: CI, confidence 
interval; NV+, norovirus positive; NV−, norovirus negative; RE, random effects.
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Susceptibility to norovirus infection based on Lewis status. Abbreviations: CI, confidence 
interval; NV+, norovirus positive; NV−, norovirus negative; RE, random effects.
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Susceptibility to rotavirus infection based on secretor status, by genotype. †Cases infected 
with 1 strain were compared with cases infected with other strains to determine odds of 
strain-specific infection (eg, P[4] infections were compared with P[6] and P[8] infections). 
Abbreviations: CI, confidence interval; RE, random effects; RV+, rotavirus positive; RV−, 
rotavirus negative.
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